Neuphoria Therapeutics Inc. Effective Tax Rate
Neuphoria Therapeutics Inc. (NEUP) reported Effective Tax Rate of 1.00% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-09-18
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, percent for the quarter ending 2026-03-31 was 6.40%.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-12-31 was -1.90%.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-09-30 was -0.35%, a 102.48% decline year-over-year.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-03-31 was -0.70%.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, percent for fiscal 2026 was 1.00%, a 98.21% decline from fiscal 2025.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, percent for fiscal 2025 was 55.90%, a 9216.67% increase from fiscal 2024.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, percent for fiscal 2024 was 0.60%, a 0.00% change from fiscal 2023.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, percent for fiscal 2023 was 0.60%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 3 month as first filed | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 9 month as first filed | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 1.00% 10-K · filed 2026-09-18 | |||||
| 2026-03-31 | 6.40% 10-Q · filed 2026-05-15 | 1.20% 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | -1.90% 10-Q · filed 2026-02-17 | 0.86% 10-Q · filed 2026-02-17 | ||||
| 2025-09-30 | -0.35% 10-Q · filed 2025-11-14 | |||||
| 2025-06-30 | 55.90% 10-K · filed 2026-09-18 | |||||
| 2025-03-31 | -0.70% 10-Q · filed 2026-05-15 | -0.73% 10-Q · filed 2025-05-20 | -2.40% 10-Q · filed 2026-05-15 | -2.43% 10-Q · filed 2025-05-20 | ||
| 2024-12-31 | -0.60% 10-Q · filed 2026-02-17 | 6.33% 10-Q · filed 2025-02-14 | 4.20% 10-Q · filed 2026-02-17 | |||
| 2024-09-30 | 14.11% 10-Q · filed 2025-11-14 | 14.10% 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | 0.60% 10-K · filed 2025-09-29 | |||||
| 2024-03-31 | -0.59% 10-Q · filed 2025-05-20 | -0.41% 10-Q · filed 2025-05-20 | ||||
| 2023-12-31 | 0.56% 10-Q · filed 2025-02-14 | |||||
| 2023-09-30 | 0.60% 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | 0.60% 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |